Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 22:10:1068330.
doi: 10.3389/fped.2022.1068330. eCollection 2022.

Understanding the effects of opioids vs non-opioids in the treatment of neonatal abstinence syndrome, an in vitro model

Affiliations

Understanding the effects of opioids vs non-opioids in the treatment of neonatal abstinence syndrome, an in vitro model

Thitinart Sithisarn et al. Front Pediatr. .

Abstract

Neonatal abstinence syndrome (NAS) refers to cadre of withdrawal manifestations in infants born to mothers who used illicit and licit substances during pregnancy. The increasing prevalence of NAS has been largely due to the maternal use of opioids during pregnancy. NAS contributes to increased morbidity and long-term disability in surviving infants. Clinically, oral opioid therapies for opioid exposure have been a standard treatment with morphine (MO) being the most commonly used medication. Recently, a non-opioid agent, clonidine (CD) has also been used with potentially favorable short- and long-term outcomes in infants. However, data regarding the cellular and molecular effects of these treatments on the developing brain is still lacking due to a lack of a reliable animal model that targets the neonatal brain. To address this gap in knowledge we determined the effects of MO or CD on the cell death of neonatal cortical explant cultures that were exposed to oxycodone (OXY) in utero. Sprague Dawley rats were randomized and implanted with programmable infusion pumps before mating to receive either the OXY (dose increasing from 1.21-1.90 mg/kg/day to a maximum dose of 2.86-3.49 mg/kg/day) or normal saline (NS) throughout pregnancy and until one week after delivery. Male and female rat pups were sacrificed on postnatal day 4, and the prefrontal cortex (PFC) and hippocampus (HC) were dissected and treated with MO (0.10-1.00 µM) or CD (1.20-120.00 µM) in culture media. After 5 days of treatment the explants were labeled with propidium iodide to detect cell death. Dead cells were analyzed and counted under fluorescence microscopy. In explants from the PFC, cell death was greater in those prenatally exposed to OXY and postnatally treated with MO (OXY/MO) (736.8 ± 76.5) compared to OXY/CD (620.9 ± 75.0; p = 0.005). In the HC explants, mean cell death counts were not significantly different between groups regardless of prenatal exposure or postnatal treatment (p = 0.19). The PFC is vital in controlling higher-order executive functions such as behavioral flexibility, learning and working memory. Therefore, our finding is consistent with executive function problems in children with prenatal opioid exposure.

Keywords: cell death; clonidine; hippocampus; in vitro model; morphine; neonatal abstinence syndrome (NAS); opioid withdrawal; prefrontal cortex.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic of pre- and post-natal treatment regimen.
Figure 2
Figure 2
Quantification of cell death in organotypic explants following treatment with clonidine or morphine. (A) Prefrontal Cortex (PFC) Explants. (B) Hippocampus (HC) explants.
Figure 3
Figure 3
Propidium iodide staining for cell death from the PFC (A) and hippocampus (B) under fluorescence microscopy, explants were prenatally exposed to NS (panel A) and to OXY (panel B) with postnatal treatment with control, clonidine and morphine respectively.

Similar articles

Cited by

References

    1. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. (2012) 307(18):1934–40. 10.1001/jama.2012.3951 - DOI - PubMed
    1. Ko JY, D'Angelo DV, Haight SC, Morrow B, Cox S, Salvesen von Essen B, et al. Vital signs: prescription opioid pain reliever use during pregnancy - 34 U.S. Jurisdictions, 2019. MMWR Morb Mortal Wkly Rep. (2020) 69(28):897–903. 10.15585/mmwr.mm6928a1 - DOI - PMC - PubMed
    1. SAMSHA. Results from the 2016 National Survery on Drug Use and Health: Detailed Tables. 2019.
    1. Patrick SW, Barfield WD, Poindexter BB, Committee On F, Newborn COSU, Prevention. Neonatal opioid withdrawal syndrome. Pediatrics. (2020) 146(5):1–18. 10.1542/peds.2020-029074 - DOI - PubMed
    1. Young LW, Hu Z, Annett RD, Das A, Fuller JF, Higgins RD, et al. Site-level variation in the characteristics and care of infants with neonatal opioid withdrawal. Pediatrics. (2021) 147(1):1–10. 10.1542/peds.2020-008839 - DOI - PMC - PubMed